The effect of adjuvants on the immune response induced by a DBL4e{open}-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria

Vaccine

Volumn 30, Issue 3, 2012, Pages 572-579

  Pinto, V V ^a,b   Salanti, A ^a,b   Joergensen, L M ^a,b   Dahlback M ^a,b   Resende, M ^a,b   Ditlev, S B ^a,b   Agger, E M ^c   Arnot, D E ^a,b   Theander, T G ^a,b   Nielsen, M A ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Chondroitin sulphate A; DBL4e open ID4; Placental malaria vaccine; Plasmodium falciparum; VAR2CSA

Indexed keywords

CAF 01; CHONDROITIN SULFATE; FREUND ADJUVANT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 720; PROTEIN; UNCLASSIFIED DRUG; VAR2CSA PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MALARIA FALCIPARUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PLACENTAL MALARIA; PRIORITY JOURNAL; PROTEIN BINDING; RAT; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL ADHESION; CHONDROITIN SULFATES; DISEASE MODELS, ANIMAL; FEMALE; MALARIA VACCINES; MALARIA, FALCIPARUM; PLACENTA DISEASES; PREGNANCY; RATS; RATS, WISTAR;

EID: 84355166389     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.068     Document Type: Article

References (43)

1. Dellicour S., Tatem A.J., Guerra C.A., Snow R.W., ter Kuile F.O. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 2010, 7(1):e1000221.
2. Su X.Z., Heatwole V.M., Wertheimer S.P., Guinet F., Herrfeldt J.A., Peterson D.S., et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995, 82(July (1)):89-100.
3. Smith J.D., Chitnis C.E., Craig A.G., Roberts D.J., Hudson-Taylor D.E., Peterson D.S., et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995, 82(1 (July)):101-110.
4. Baruch D.I., Pasloske B.L., Singh H.B., Bi X., Ma X.C., Feldman M., et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995, 82(1 Jul 14):77-87.
5. David P.H., Hommel M., Miller L.H., Udeinya I.J., Oligino L.D. Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes. Proc Natl Acad Sci USA 1983, 80(August (16)):5075-5079.
6. Achur R.N., Valiyaveettil M., Alkhalil A., Ockenhouse C.F., Gowda D.C. Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta. J Biol Chem 2000, 275(December (51)):40344-40356.
7. Achur R.N., Valiyaveettil M., Gowda D.C. The low sulfated chondroitin sulfate proteoglycans of human placenta have sulfate group-clustered domains that can efficiently bind Plasmodium falciparum-infected erythrocytes. J Biol Chem 2003, 278(March (13)):11705-11713.
8. Muthusamy A., Achur R.N., Bhavanandan V.P., Fouda G.G., Taylor D.W., Gowda D.C. Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. Am J Pathol 2004, 164(June (6)):2013-2025.
9. Uneke C.J. Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa. II. Effects of placental malaria on perinatal outcome; malaria and HIV. Yale J Biol Med 2007, 80(September (3)):95-103.
10. Rogerson S.J., Hviid L., Duffy P.E., Leke R.F., Taylor D.W. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 2007, 7(February (2)):105-117.
11. Fried M., Nosten F., Brockman A., Brabin B.J., Duffy P.E. Maternal antibodies block malaria. Nature 1998, 395(October (6705)):851-852.
12. Salanti A., Dahlback M., Turner L., Nielsen M.A., Barfod L., Magistrado P., et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004, 200(November (9)):1197-1203.
13. Nielsen M.A., Pinto V.V., Resende M., Dahlback M., Ditlev S.B., Theander T.G., et al. Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun 2009, 77(June (6)):2482-2487.
14. Stills H.F. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 2005, 46(3):280-293.
15. Malkin E., Hu J., Li Z., Chen Z., Bi X., Reed Z., et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008, 26(December (52)):6864-6873.
16. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005, 73(December (12)):8017-8026.
17. Mbow M.L., De G.E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22(June (3)):411-416.
18. Esen M., Kremsner P.G., Schleucher R., Gassler M., Imoukhuede E.B., Imbault N., et al. Safety and immunogenicity of G. Vaccine 2009, 27(November (49)):6862-6868.
19. Mordmuller B., Szywon K., Greutelaers B., Esen M., Mewono L., Treut C., et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine 2010, September (28)(41):6698-6703.
20. Sirima S.B., Tiono A.B., Ouedraogo A., Diarra A., Ouedraogo A.L., Yaro J.B., et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One 2009, 4(10):e7549.
21. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(February (1)):23-29.
22. De G.E., D'Oro U., Wack A. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 2009, 21(June (3)):339-345.
23. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314(December (5807)):1936-1938.
24. Ishii K.J., Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007, 27(July (4)):363-371.
25. Holten-Andersen L., Doherty T.M., Korsholm K.S., Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004, 72(March (3)):1608-1617.
26. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3(9):e3116.
27. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005, 1718(December (1-2)):22-31.
28. Haase R.N., Megnekou R., Lundquist M., Ofori M.F., Hviid L., Staalsoe T. Plasmodium falciparum parasites expressing pregnancy-specific variant surface antigens adhere strongly to the choriocarcinoma cell line BeWo. Infect Immun 2006, 74(May (5)):3035-3038.
29. Magistrado P.A., Staalsoe T., Theander T.G., Hviid L., Jensen A.T. CD36 selection of 3D7 Plasmodium falciparum associated with severe childhood malaria results in reduced VAR4 expression. Malar J 2008, 7:204.
30. Nielsen M.A., Resende M., Alifrangis M., Turner L., Hviid L., Theander T.G., et al. Plasmodium falciparum: VAR2CSA expressed during pregnancy-associated malaria is partially resistant to proteolytic cleavage by trypsin. Exp Parasitol 2007, 117(September (1)):1-8.
31. Joergensen L., Bengtsson D.C., Bengtsson A., Ronander E., Berger S.S., Turner L., et al. Surface co-expression of two different PfEMP1 antigens on single Plasmodium falciparum-infected erythrocytes facilitates binding to ICAM1 and PECAM1. PLoS Pathog 2010, 6(9):e1001083.
32. Salanti A., Resende M., Ditlev S.B., Pinto V.V., Dahlback M., Andersen G., et al. Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies. Malar J 2010, 9:11.
33. Fernandez P., Petres S., Mecheri S., Gysin J., Scherf A. Strain-transcendent immune response to recombinant Var2CSA DBL5-epsilon domain block P. falciparum adhesion to placenta-derived BeWo cells under flow conditions. PLoS One 2010, 5(9):e12558.
34. Magistrado P.A., Minja D., Doritchamou J., Ndam N.T., John D., Schmiegelow C., et al. High efficacy of anti DBL4varepsilon-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine 2011, 29(January (3)):437-443.
35. Miles A.P., McClellan H.A., Rausch K.M., Zhu D., Whitmore M.D., Singh S.M., et al. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005, 23(March (19)):2530-2539.
36. Genton B., Al-Yaman F., Anders R., Saul A., Brown G., Pye D., et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000, 18(May (23)):2504-2511.
37. Giraldo M.A., Arevalo-Pinzon G., Rojas-Caraballo J., Mongui A., Rodriguez R., Patarroyo M.A. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection. Vaccine 2009, 28(December (1)):7-13.
38. Saul A., Hensmann M., Sattabongkot J., Collins W.E., Barnwell J.W., Langermans J.A., et al. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite Immunol 2007, 29(October (10)):525-533.
39. Du C., Nilsson S., Lu H., Yin J., Jiang N., Wahlgren M., et al. Immunogenicity of the Plasmodium falciparum Pf332-DBL domain in combination with different adjuvants. Vaccine 2010, (May).
40. Chowdhury D.R., Angov E., Kariuki T., Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 2009, 4(7):e6352.
41. Philips J.R., Brouwer W., Edwards M., Mahler S., Ruhno J., Collins A.M. The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model. Immunol Cell Biol 1999, 77(April (2)):121-126.
42. Barfod L., Bernasconi N.L., Dahlback M., Jarrossay D., Andersen P.H., Salanti A., et al. Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol 2007, 63(January (2)):335-347.
43. Joergensen L.M., Salanti A., Dobrilovic T., Barfod L., Hassenkam T., Theander T.G., et al. The kinetics of antibody binding to Plasmodium falciparum VAR2CSA PfEMP1 antigen and modelling of PfEMP1 antigen packing on the membrane knobs. Malar J 2010, 9:100.